Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoSep1 neonatal sepsis antibiotic ranking study
ISRCTN48721236Phase 4Recruiting
- Sponsor
- GARDP
- Start
- Mar 2023
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
01
Overview
Phase 4, randomised, open-label trial of fosfomycin, flomoxef, amikacin, ampicillin, amoxicillin and 8 more in neonatal sepsis (5 arms), sponsored by GARDP. Started Mar 2023; status: recruiting.
02
Drugs
fosfomycinflomoxefamikacinampicillinamoxicillin
03
Conditions
neonatal sepsis
Beyond the preview
Go deeper on ISRCTN48721236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN48721236.